



## ORIGINALES

## Medication non-adherence as a cause of hospital admissions

M. Álvarez Payero, N. Martínez López de Castro, M. Ucha Samartín, A. Martín Vila, C. Vázquez López y G. Piñeiro Corrales

Servicio de Farmacia. Complejo Hospitalario Universitario de Vigo. Xerencia de Xestión Integrada de Vigo.

### Abstract

**Objectives:** 1. To determine the profile of patients who are admitted to hospital as a result of non-adherence. 2. To obtain an estimate of the economic impact for the hospital.

**Methods:** Observational and retrospective study that included patients who were admitted to hospital with a secondary diagnosis of «Personal history of non-compliance with chronic medication» according to International Classification of Diseases, during 2012. Data collected: demographics; socioeconomic and clinical data; data related to the treatment; readmissions; hospital days; degree of adherence:  $\leq 75\%$  or severe non-adherence and  $> 75\%$  or moderate non-adherence; type of non-adherence: non-persistence and non-compliance; hospitalization costs. Statistical analysis was performed. Results: Eighty-seven patients were admitted. These patients caused 104 episodes (16.3% were readmissions). 71.2% were men, and 51.5 (SD 17.8) years old. All patients had a chronic disease, adherence  $\leq 75\%$  (76%) and non-persistence (63.5%). Polypharmacy (47.1%) was not associated with non-adherence. Total stay was 1,527 days (mean stay was 14.7 (SD 14.0) days/episode): psychiatry 827 days (54.2%); cardiology 174 days (11.4%); critical unit 48 days (3.1%). Patients with a degree of adherence  $\leq 75\%$  had a mean stay/episode higher than those with a degree of adherence  $> 75\%$ , without significant differences ( $p > 0.05$ , t-Student). Overall cost of hospitalization was € 594,230.8, with a mean cost/episode: € 5,713.6 (SD 5,039.5). Mean cost/episode for adherence  $\leq 75\%$  was higher than  $> 75\%$ , € 6,275.8 (SD 5,526.2) vs € 3,895.6 (SD 2,371.3), ( $p < 0.05$ , t-Student).

**Conclusions:** The profile of this patient is fundamentally, a male psychiatric or chronic cardiac patient with a degree of adherence  $\leq 75\%$  due to abandoning domiciliary treatment. Admissions due to medication non-adherence are associated with an important depletion of economic resources in the hospital.

### KEYWORDS

Adherence; Hospitalization; Persistence; Costs; Domiciliary medication

Farm Hosp. 2014;38(4):328-333

### Falta de adherencia al tratamiento como causa de hospitalización

### Resumen

**Objetivo:** 1. Determinar el perfil del paciente hospitalizado por falta de adherencia. 2. Estimar el impacto económico generado al hospital.

**Método:** Estudio retrospectivo observacional, en pacientes hospitalizados con diagnóstico secundario de «historia personal de no cumplimiento del tratamiento crónico» según la Clasificación Internacional de Enfermedades, durante 2012. Variables recogidas: demográficas; datos socio-económicos y clínicos; datos relacionados con el tratamiento; reingresos; estancia (días); grado de adherencia:  $\leq 75\%$  o no adherencia severa y  $> 75\%$  o no adherencia moderada; tipo no adherencia: no persistencia e incumplimiento; costes de hospitalización. Se realizó análisis estadístico.

**Resultados:** Ingresaron 87 pacientes generando 104 episodios (16,3% reingresos). El 71,2% fueron hombres con una edad media de 51,5 (DE 17,8) años. Todos los pacientes tenían una patología crónica, el 76% una adherencia  $\leq 75\%$  y el 63,5% falta de persistencia. La polifarmacia (47,1%) fue independiente del grado de adherencia. La estancia total fue 1.527 días (estancia media de 14,7 (DE 14,0) días/episodio): psiquiatría 827 días (54,2%); cardiología 174 días (11,4%); unidad de críticos 48 días (3,1%). Los pacientes con un grado de adherencia  $\leq 75\%$  tuvieron una estancia media mayor que los pacientes con un grado de adherencia  $> 75\%$ , aunque no alcanzó significación estadística ( $p > 0,05$ , t-Student). El coste total fue de 594.230,8 € con un coste medio de 5.713,6 (DE 5.039,5) €/episodio. El coste medio de hospitalización en pacientes con adherencia  $\leq 75\%$  fue mayor que en el caso de adherencia  $> 75\%$ , 6.275,8 (DE 5.526,2) € vs 3.895,6 (DE 2.371,3) €, ( $p < 0,05$ , t-Student).

**Conclusiones:** El perfil de este tipo de paciente es fundamentalmente, varón psiquiátrico o cardiológico crónico, con adherencia  $\leq 75\%$  por abandono del tratamiento. Las hospitalizaciones por falta de adherencia al tratamiento generan un importante consumo de recursos económicos en el hospital.

### PALABRAS CLAVE

Adherencia; Hospitalización; Persistencia; Costes; Tratamiento domiciliario

Farm Hosp. 2014;38(4):328-333

\* Autor para correspondencia.

Correo electrónico: miriamal\_5@hotmail.com (Miriam Álvarez Payero).

## Introduction

The World Health Organization (WHO) defines the concept of adherence as<sup>1</sup> «the extent to which a person's behavior - taking medication, following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a health care provider». In chronic treatments, three complementary concepts interact: acceptance of the disease, compliance (taking the medication, in the short-term, according to the prescription) and persistence in time (continuous medication aimed at getting long-term clinical benefit). To obtain a good therapeutic result a degree of adherence (DA) higher than 80% is generally considered to be acceptable, although the ideal value would be greater than 95%<sup>1</sup>. Clinical practice data indicate that the rate of adherence in chronic diseases is variable (30-100%)<sup>2-5</sup>. Nevertheless, it is generally low and independent of the disease. Various factors such as forgetfulness or confusion explain involuntarily poor adherence to therapy. On the other hand, others factors such as the chronicity of the disease, fear of adverse reactions, polypharmacy, lack of understanding, sociocultural and economic factors, may condition a lack of voluntary adherence<sup>6</sup>.

Non-adherence is a major world public health problem, due to its negative consequences both for the patient: worse clinical results, quality of life and greater morbidity and mortality<sup>7</sup>; and for the health system<sup>1,6-7</sup>. It is estimated that non-adherence generates an annual cost of \$100 billion in the United States<sup>6-7</sup> and 125 billion Euros (€) in Europe<sup>8</sup>. In Spain this figure could be estimated at 11 thousand million € per year<sup>8</sup>.

Numerous works<sup>2-5,9-12</sup> evaluate the DA in different diseases, the causes of non-compliance and abandonment, and refer to the important economic impact this degree of adherence has. Nonetheless, on the other hand, few works<sup>13</sup> sub-analyse the role of non-adherence as a cause of hospitalization.

The objectives of this study are:

1. To determine the profile of patients who are hospitalized as a result of non-adherence to domiciliary pharmacological treatment.
2. To obtain an estimate of the economic impact for the hospital.

## Method

We performed an observational retrospective study conducted in a 1,250-bed university hospital. We included patients over 18 years old that were admitted in 2012 with a secondary diagnosis of «Personal history of non-compliance with chronic medication» (code V15.81) of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) format. We obtained the initial sample of patients from the cod-

ing department of the hospital and other data by digital medical record (IANUS® v.04.10.0323). Variables collected: demographics; Charlson comorbidity score<sup>14</sup>; obesity (referenced in medical record); basal diagnosis (according to ICD-9-CM); hospitalization unit; socioeconomic data (level of education, type of residence, residential area, living alone/accompanied, work activity, active toxic habits: tobacco, alcohol and drugs); number (No.) of domiciliary medicines (DM) on admission; polypharmacy ( $\geq 5$  drugs)<sup>15</sup>; therapeutic group (according to official Anatomical, Therapeutic, Chemical classification (ATC) system); type of medication dispensed: hospital (HD) /community (CD); hospital days; re-admissions (days); DA, we defined:  $\leq 75\%$  or *severe non-adherence* (unjustified discontinuity of  $\geq 1$  month in the collection of medication from the pharmacy and/or hospital outpatient dispensing area, in the 4 months prior to admission) and  $> 75\%$  or *moderate non-adherence* (no discontinuity in the collection); type of non-adherence: we defined *non-persistence* (proof of abandonment of the treatment in the medical report on release from the hospital) and *non-compliance* (evidence of irregular intake of medicines in the medical report); hospitalization prevalence; hospitalization costs (overall cost, cost per episode, cost per unit and cost of re-admission). In order to estimate the economic impact we only evaluated the cost associated with the hospital stay, according to Royal Decree-Law 221/2012, 31 October, in which the rates for health services provided at the centres of the Galician health service are established (taking into account the difference in the cost for acute psychiatric and critical care units).

We performed descriptive statistical analysis expressing the quantitative variables such as mean (standard deviation) and the categorical such as percentages and frequencies using the SPSS version 15 programme. We associated the degree and type of non-adherence with the categorical variables using contingency and Chi-square tables; and using the T-Student test and variance analysis (ANOVA) with the quantitative variables. We established a significance level of  $p < 0.05$ .

## Results

A total of 106 patients were admitted with a secondary diagnosis of lack of adherence to medication. Nineteen patients were excluded from the study because the relationship between the reason for admission and non-adherence to DM did not exist, or was unclear. The 87 patients with a confirmed diagnosis, resulted in 104 hospitalizations or episodes (seven patients were readmitted once, and three patients were readmitted two or more times). There were four exitus in patients with human immunodeficiency virus (HIV): three due to acquired immunodeficiency syndrome and one due to pneumococcal sepsis.

All of the patients had basal chronic pathologies, which were primarily psychiatric or cardiac in origin. Table 1 gives the general and clinical characteristics of the hospitalized patients.

The cardiologic patients took more DM than the psychiatric [6.9 (4.0) vs. 4.2 (2.4) drugs,  $p < 0.05$ , ANOVA]; although polypharmacy and the number of DM was not related to the degree or type of non-adherence, ( $p > 0.05$ , Chi-square and t-Student test). All of the HD drugs were antiretrovirals for HIV.

Severe lack of adherence was identified in 76% (79/104) of episodes. Patients with mental illness (ICD-9-CM, codes 290.0-319.9) had a DA  $\leq 75\%$  in 70.3% (26/37) of psychiatric episodes and in 8.7% with respect to total admissions to psychiatry unit (26/297) in 2012. Patients with cardiac disorders had a severe non-adherence in 63.6% (14/22) of cardiologic episodes. The mean age in patients with severe lack of adherence ( $\leq 75\%$ ) was lower than in moderate non-adherence ( $> 75\%$ ): 48.5 (16.7) vs. 60.4 (18.2) years in moderate,  $p < 0.05$ , t-Student. There was non-persistence in the treatment in 63.5% of the cases, with this being the main reason for the lack of adherence in therapeutic groups N (nervous system), C (circulatory system), R (respiratory system) and J (anti-infective).

Other significant differences did not observe among the rest of the clinical, socioeconomic and demographic characteristics of the patients for DA and type of non-adherence.

Table 2 gives the total and mean hospital stay for the episodes and re-admissions with respect to hospitalization units.

The hospitalization units with increased overall and longer average stays per episode were psychiatry and cardiology with 54.2% and 11.4% of the cumulative total, respectively. We recorded that 10.6% of the total number of cases were in the intensive care unit; with a total stay of 48 days, but with a short mean length of stay in this unit per episode (standard deviation), 0.5 (1.7) days. Furthermore, 16.3% (17/104) of the total cases were re-admissions; mainly psychiatric (64.7%) and respiratory (23.5%) patients.

Table 3 gives the stay and the average cost in each case of hospitalization depending on the DA and type of non-adherence.

Patients with a DA  $\leq 75\%$  had a length of hospitalization/episode higher than those with a DA  $> 75\%$ ; nevertheless, no statistically significant difference was observed,  $p > 0.05$ , t-Student test.

The average costs associated with hospitalization resulting from a severe non-adherence (DA  $\leq 75\%$ ) and those caused by lack of persistence to treatment were significantly higher than in hospital admissions due to moderate non-adherence or slight interruption of treatment,  $p < 0.05$ , t-Student test (Table 3). Overall cost of hospitalization was € 594,230.8 (€ 203,829.88 in psy-

**Table 1.** Clinical, socioeconomic and demographic characteristics of the patients in the cases of hospitalization included in the study (n = 104)

Variables	Results
Sex (male)	71.2
Age <sup>a</sup> (mean; SD)	51.5 (17.8)
CCS	
0-3	49.0
4-9	32.7
$\geq 10$	18.3
Obesity <sup>b</sup>	19.2
ICD-9-CM <sup>c</sup>	
Mental illness	36.5
Circulatory system	26.9
Respiratory system	10.6
Other	26.0
Hospitalization unit	
Psychiatry	34.6
Cardiology	19.2
Internal Medicine	11.5
Intensive Care Unit	10.6
Pneumology	9.6
Other <sup>c</sup>	14.5
Lives	
Alone	21.2
Accompanied	68.3
Without data	10.6
Residence	
Home	93.3
Institution	1.0
Indigent	5.8
Residential area	
Urban	51.0
Rural	43.3
Without data	5.8
Actively working	28.8
Active toxic habits <sup>e</sup>	61.5
Alcohol	41.3
Tobacco	39.4
Drugs	22.1
No. Domiciliary medication (mean; SD)	7.2 (3.4)
Polypharmacy ( $\geq 5$ drugs)	47.1
Therapeutic group <sup>f</sup>	
N. Nervous system	40.4
C. Cardiovascular system	29.8
R. Respiratory system	9.6
Other	20.2
Type of dispensation	
Community	92.3
Hospital	7.7

CCS: Charlson Comorbidity Score; SD: Standard deviation.

<sup>a</sup>Age in years; <sup>b</sup>obesity: referenced in medical record; <sup>c</sup>ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical Modification, refers to the underlying chronic disease and is related to the diagnosis on admission in 100% of cases. Mental illness (codes 290.0-319), circulatory system (codes 390.0-459.9), respiratory system (codes 460.0-519.9); <sup>d</sup>Other: endocrine, digestive, geriatrics and nephrology; <sup>e</sup>Baseline count of patients who have active toxic habits. There are patients with more than one toxic habit; <sup>f</sup>According to Anatomical, Therapeutic, Chemical classification system.

\*The variable "level of education" is not recorded since in 73.1% of cases it could not be assessed due to lack of information, in medical records.

**Table 2.** Accumulated total stay and average hospital stay for episodes of hospitalization and readmission

Variables	Total hospital stay Days (%)	Hospital Stay/episode Average (SD)
Total episodes N = 104	1,527 (100%)	14.7 (14.0)
Hospitalization unit		
Psychiatry	827 (54.2%)	20.7 (16.8)
Cardiology	174 (11.4%)	9.2 (6.3)
Intensive Care Unit	48 (3.1%)	0.5 (1.7)
Other <sup>a</sup>	478 (31.3%)	11.7 (11.9)
Re-admissions (n = 17)	244 (16.0%)	15.1 (14.1)
Re-admission unit		
Psychiatry	208 (85.2%)	18.9 (12.6)
Pneumology	21 (8.6%)	5.3 (2.2)
Other <sup>b</sup>	15 (6.2%)	7.5 (0.7)

Average hospital stay in days; SD: Standard deviation.

<sup>a</sup>Other: pneumology, internal medicine, endocrine, digestive, neurology, geriatrics, nephrology, haemato-logy, rheumatology, oncology; <sup>b</sup>Other: cardiology and internal medicine.

chiatry, € 84,566.6 in the intensive care unit and the rest due to hospitalization in other medical units), with an average cost/episode of € 5,713.6 ± 5,039.5. Re-admission cases amounted to € 83,211.3.

The hospitalization prevalence due to lack of adherence to DM, was 0.30% (104/ 34,195) for adults, in period of study.

## Discussion

This study showed that 76% of the cases took less than 75% of their chronic medication during the four previous months. In the majority of the cases, this was because the patient abandoned the treatment. This also causes a longer hospital stay with respect to the average global hospital stay (8.6 days). Nonetheless, we cannot confirm if this finding is significant due to lack of a group

control. These patients were mainly young men with little co-morbidity (although in the study period the majority of the scheduled admissions for other causes were for women). These results are similar to those found by Ambadekar<sup>16</sup> in cardiology patients. Other studies in chronic obstructive pulmonary disease patients<sup>4</sup> point to the elderly with comorbidities as being less adherent, and Flovig<sup>13</sup> points to a lower DA in women with psychiatric pathologies.

Although the presence of polypharmacy is important (47.1%), is not associated with lower adherence, in our study. This finding coincides with other authors<sup>17</sup> where the number of daily tablets taken for antiretrovirals are not associated with adherence (10.6 (4.6) vs 9.5 (3.2) tablets). This relationship, between polypharmacy and poor adherence, appears to be greater in the frail elderly and pluripathological patient<sup>18-19</sup>. Whenever possible, the medication regimen should be simplified.

In this study, patients with psychiatric illness have a severe non-adherence (DA ≤ 75%) to medication regime. A lack of adherence for psychiatric treatment was recorded by literature; Cramer et al.<sup>20</sup>, showed a mean level of adherence for antipsychotic medication of 58 (19) percent (range 24-90 percent). Hong et al.<sup>21</sup> estimated non-adherence rate (23.6%) over 21 months follow-up in the treatment of bipolar disorder. A recent study<sup>13</sup> in psychiatric patients, analysed the adherence of the week prior to admission and found 15% of DA < 75% (and 82% of DA > 75%). In our case, we obtained a higher percentage (72.2%) of DA ≤ 75% for psychiatric patient cohort (26/36) in the 4 months prior to admission. Although it is not comparable since the methodology differs, the high adherence to medication one week prior to admission might be related to increased experience of serious symptoms.

In a meta-analysis<sup>22</sup>, non-adherence was shown to be > 1.5 times higher among individuals who did not perceive their disease as severe or as a threat. To achieve optimal adherence, the first step is to accept the disease and actively engage in its treatment and this seems to be

**Table 3.** Description of the hospital stay and cost generated for hospitalization episodes depending on the degree and type of non-adherence

Variables	Hospital Stay/episode Average (SD)	p value*	Cost/episode of hospitalization Average (SD)	p value*
<i>Degree of adherence (DA)</i>				
≤ 75% severe non-adherence	15.54 (15.22)	p > 0.05	6,275.8 (5,526.2)	P < 0.05
> 75% moderate non-adherence	11.40 (9.4)		3,895.6 (2,371.3)	
<i>Type of non-adherence</i>				
Non-persistence	16.7 (15.7)	P > 0.05	6,722.9 (5,775.5)	P < 0.05
Non-compliance	10.8 (9.9)		3,933.2 (2,695.1)	

Average hospital stay in days; Average cost in €; SD: Standard deviation; \*T-Student test for equality of means.

one of the main problems identified in psychiatric patients (little or no awareness of their illness)<sup>1</sup>. Unfortunately, with the data available, we do not know if non-adherence is voluntary or involuntary. Nevertheless, substance abuse as alcohol (41%) and drugs (22%) seem to be common in our patients' habits, which leads us to think that voluntary abandonment probably predominates. This perception is similar to reported in other studies<sup>17,23</sup>, although our study, the active toxic habits showed no statistical significance for DA. For example, Riera et al.<sup>17</sup> concluded that active consumption of toxic and psychiatric problems, mainly depression, seem determinants on adherence to antiretroviral drugs; In recent study, Hapangama et al.<sup>23</sup> found a significant proportion (43%, range 39-48) of mentally ill patients that have a comorbid substance use diagnosis and associated complications. They were also found to have poorer treatment adherence (56.9% of them were substance abusers), increased number of hospital admissions (55.3% of readmissions corresponded to substance abusers), and higher rates of violence. For diabetes, dyslipidemia, and hypertension, medication non-adherence has been associated, also, with higher hospitalization rates<sup>22,24</sup>.

Lack of adherence as a cause for hospitalizations is associated with a high economic impact in our study, ( $p < 0.05$ , t-Student). These results are consistent with other studies<sup>9,21,25</sup> which evaluate the cost associated with non-adherence in different diseases, although the amounts differ due to the difference in the type of patient and the methodology. In a review, Touchette et al.<sup>24</sup> described that total disease-related health care costs were lower for adherent diabetic patients compared with nonadherent patients (\$4,570 for DA of 80%-100% vs. \$8,867 for DA of 0%-19%). Similarly, adherent patients with dyslipidemia had lower total disease-related health care costs than did nonadherent patients (\$ 3,924 for DA of 80%-100% of vs. \$ 6,888 for DA of 0%-19%). In our study, costs generated for hospitalizations were € 3,895.6 for episodes with DA > 75% vs. € 6,275.8 for episodes with DA ≤ 75%; our result is similar to previous if we consider \$ instead €.

## Limitations

This study has several limitations which are related to the nature of patient cohort and data used, study design, variable definitions and measure of DA and cost.

First, it is likely that the prevalence of hospitalization (0.30%) has been underestimated because we start from a sample which was already defined as such according to the encoding of the doctors. This leads us to believe that the magnitude of the problem in our area would be higher. Therefore, once again the problem of insufficient adherence that exists in the chronic patients manifests itself.

Second limitation is the retrospective design without a control group. Thus new prospective controlled studies

are needed to more firmly demonstrate our results, evaluating socioeconomic characteristics that we did not cover, or that could not be adequately assessed due to lack of information, and by measuring the DA with more appropriate methods such as validated questionnaires. In the same way, in the subgroup of psychiatric patients, it is necessary to learn more about their diagnoses, socioeconomic and pharmacotherapeutic profiles and record the influence on the DA.

Third, as we considered a value of DA > 75% as being the optimal, while the literature<sup>1</sup> establishes it as > 80% may limit comparisons. This is justified by the difficulty of retrospectively assessing the adherence with the data available (we considered 4 months so it is easier to divide the adherence into four parts (25-50-75-100%). If during at least one month, the patient did not collect their medication the adherence was taken to be ≤ 75%.

Fourth, to compare our work with others is difficult because there are few existing works that sub-analyse hospitalisations resulting from a complication of the basal disease due to the lack of adherence to domiciliary medication.

Fifth, we consider the economic valuation to be underestimated as it does not include indirect costs, emergency visits, tests or surgical procedures. Finally, the degree to which medication use may be impacted appears to depend on the patient's ability to pay for medications as well as the condition being treated<sup>24</sup>. Taking into account that in 29% of the cases the patients are actively working, and in 71% of the cases they are retired or unemployed; it would be interesting to study the costs due to loss of productivity during hospitalization and the influence that the new Spanish regime of pharmaceutical delivery has had (Royal Decree-Law 16/2012, April 20) on adherence to medication.

This study shows that the profile of the patient with hospitalization due to insufficient adherence to medication is fundamentally, male psychiatric or chronic cardiac patient, with a DA ≤ 75% due to abandoning domiciliary medication. Patients with psychiatric and/or respiratory pathologies generate successive re-admissions and others are sent to critical care unit. All this generates long hospital stays with an elevated average cost of hospitalization which are associated with an important depletion of economic resources in the hospital.

Preventive measures in the short-term, such as the establishment of follow-up units for patients with increased risk, adaptations of dosing and/or presentations regimes could be implanted. This would be also very cost-effective for the health system, in view of the results.

## Bibliography

1. World Health Organization. Adherence to long-term therapies: Evidence for action. Geneva. World Health Organization; 2003. Available at: [http://www.who.int/chp/knowledge/publications/adherence\\_report/en/](http://www.who.int/chp/knowledge/publications/adherence_report/en/). Accessed July 23, 2013.

2. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Prevalence and economic consequences of medication adherence in diabetes: A systematic literature review. *Manag Care Interface*. 2006;19: 31-41.
3. Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan *versus* other antihypertensive drug classes. *Clin Ther*. 2001; 23: 1999-2010.
4. Bourbeau J, Bartlett SJ. Patient adherence in COPD. *Thorax*. 2008; 63: 831-8.
5. Williams M, Clarke T, Williams P, Barton EN. The mean levels of adherence and factors contributing to non-adherence in patients on highly active antiretroviral therapy. *West Indian Med J*. 2007; 56: 270-4.
6. Osterberg L, Blaschke T. Adherence to medication. *N Engl J Med*. 2005; 353: 487-97.
7. New England Healthcare Institute. Thinking outside the pillbox. A system-wide approach to improving patient medication adherence for chronic disease. August 12, 2009. Available at: [http://www.nehi.net/publications/44/thinking\\_outside\\_the\\_pillbox\\_a\\_system-wide\\_approach\\_to\\_improving\\_patient\\_medication\\_adherence\\_for\\_chronic\\_disease](http://www.nehi.net/publications/44/thinking_outside_the_pillbox_a_system-wide_approach_to_improving_patient_medication_adherence_for_chronic_disease). Accessed July 23, 2013.
8. Bioindustries Unit and Pharmacy. Antares Consulting. Economic impact of non-adherence in pharmaceutical costs. Third newsletter. February 5, 2013. Available to: [http://www.antares-consulting.com/es\\_ES/main/detallepublicacion/Publicacion/79/apartado/B/idUnidad/1](http://www.antares-consulting.com/es_ES/main/detallepublicacion/Publicacion/79/apartado/B/idUnidad/1). Accessed July 27, 2013.
9. Desborough JA, Sach T, Bhattacharya D, Holland RC, Wright DJ. A cost-consequences analysis of an adherence focused pharmacist-led medication review service. *Int J Pharm Pract*. 2012; 20: 41-9.
10. Ventura-Cerdá JM, Mínguez-Gallego C, Fernández-Villalba EM, Alós-Almiñana M, Andrés-Soler J. Escala simplificada para detectar problemas de adherencia (ESPA) al tratamiento antirretroviral. *Farm Hosp*. 2006; 30: 171-6.
11. Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. *J Neurol*. 2009; 256: 568-76.
12. Santolaya Perrín R, Fernández-Pacheco García Valdecasas M, Artech Eguizabal L, Gema Pérez Pérez I, Muñoz Muñoz N, Ibarra Barrueta O et al. Adherencia subóptima al tratamiento en la esclerosis múltiple. *Farm Hosp*. 2012; 36: 124-9.
13. Flovig JC, Morken G, Güzey IC, Vaaler AE. Pharmacological treatment and adherence one week prior to acute psychiatric admissions. *Nord J Psychiatry*. 2012; 66: 222-4.
14. Charlson ME, Pompei P, Ales KL, McKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chron Dis*. 1987; 40: 373-83.
15. Monane M, Monane S, Semla T. Optimal medication use in elders. Key to successful aging. *West J Med*. 1997; 167: 233-7.
16. Ambardekar AV, Fonarow GC, Hernandez AF, Pan W, Yancy CW, Krantz MJ. Characteristics and in-hospital outcomes for nonadherent patients with heart failure: Findings from Get With The Guidelines-Heart Failure (GWTG-HF). *Am Heart J*. 2009; 158: 644-52.
17. Riera M, De la Fuente L, Castanyer B, Puigventós F, Villalonga C, Ribas MA et al. Adherencia a los fármacos antirretrovirales medida por la concentración de fármacos y el recuento de comprimidos. Variables relacionadas con una mala adherencia. *Med Clin (Barc)*. 2002; 119: 286-92.
18. Shah BM, Hajjar ER. Polypharmacy, adverse drug reactions, and geriatric syndromes. *Clin Geriatr Med*. 2012; 28: 173-86.
19. Hubbard RE, O'Mahony MS, Woodhouse KW. Medication prescribing in frail older people. *Eur J Clin Pharmacol*. 2013; 69: 319-26.
20. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. *Psychiatr Serv*. 1998; 49: 196-201.
21. Hong J, Reed C, Novick D, Haro JM, Aguado J. Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study. *Psychiatry Res*. 2011; 190: 110-4.
22. DiMatteo MR, Haskard KB, Williams SL. Health beliefs, disease severity, and patient adherence: a meta-analysis. *Med Care*. 2007; 45: 521-8.
23. Hapangama A, Kurupparachchi KA, Pathmeswaran A. Substance use disorders among mentally ill patients in a General Hospital in Sri Lanka: prevalence and correlates. *Ceylon Med J*. 2013; 58: 111-5.
24. Touchette D, Shapiro NL. Medication Compliance, Adherence, and Persistence: Current Status of Behavioral and Educational Interventions to Improve Outcomes. *J Manag Care Pharm*. 2008; 14 (Suppl. S-d): S2-S10.
25. Sun SX, Liu GG, Christensen DB, Fu AZ. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. *Curr Med Res Opin*. 2007; 23: 2305-12.